Evidence map›Paper›PMID 35356783›Full record

ArticleFrontiers in bioengineering and biotechnology2022

A Biofabrication Strategy for a Custom-Shaped, Non-Synthetic Bone Graft Precursor with a Prevascularized Tissue Shell.

Sarah M Moss, Monica Ortiz-Hernandez, Dmitry Levin, Chris A Richburg, Thomas Gerton, Madison Cook, Jeffrey J Houlton, Zain H Rizvi, Paul C Goodwin, Michael Golway and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Extrusion bioprinting: meeting the promise of human tissue biofabrication?Progress in biomedical engineering (Bristol, England) · 2025
    Review
  4. Article
  5. Vascularized Tissue Organoids.Bioengineering (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Sarah M MossAdvanced Solutions Life Sciences, Louisville, KY, United States.
Monica Ortiz-HernandezVeterans Affairs Puget Sound Health Care System, Seattle, WA, United States.
Dmitry LevinVeterans Affairs Puget Sound Health Care System, Seattle, WA, United States.
Chris A RichburgVeterans Affairs Puget Sound Health Care System, Seattle, WA, United States.
Thomas GertonAdvanced Solutions Life Sciences, Louisville, KY, United States.
Madison CookAdvanced Solutions Life Sciences, Louisville, KY, United States.
Jeffrey J HoultonVeterans Affairs Puget Sound Health Care System, Seattle, WA, United States.
Zain H RizviVeterans Affairs Puget Sound Health Care System, Seattle, WA, United States.
Paul C GoodwinCytiva, Seattle, WA, United States.
Michael GolwayAdvanced Solutions Life Sciences, Louisville, KY, United States.
Beth RipleyVeterans Affairs Puget Sound Health Care System, Seattle, WA, United States.
James B HoyingAdvanced Solutions Life Sciences, Louisville, KY, United States.
University of Washington · USVA Puget Sound Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Critical-sized defects of irregular bones requiring bone grafting, such as in craniofacial reconstruction, are particularly challenging to repair. With bone-grafting procedures growing in number annually, there is a reciprocal growing interest in bone graft substitutes to meet the demand. Autogenous osteo(myo)cutaneous grafts harvested from a secondary surgical site are the gold standard for reconstruction but are associated with donor-site morbidity and are in limited supply. We developed a bone graft strategy for irregular bone-involved reconstruction that is customizable to defect geometry and patient anatomy, is free of synthetic materials, is cellularized, and has an outer pre-vascularized tissue layer to enhance engraftment and promote osteogenesis. The graft, comprised of bioprinted human-derived demineralized bone matrix blended with native matrix proteins containing human mesenchymal stromal cells and encased in a simple tissue shell containing isolated, human adipose microvessels, ossifies when implanted in rats. Ossification follows robust vascularization within and around the graft, including the formation of a vascular leash, and develops mechanical strength. These results demonstrate an early feasibility animal study of a biofabrication strategy to manufacture a 3D printed patient-matched, osteoconductive, tissue-banked, bone graft without synthetic materials for use in craniofacial reconstruction. The bone fabrication workflow is designed to be performed within the hospital near the Point of Care.

Indexed as

3D bioprintingbonecraniofacialossificationpatient-specificreconstructiontissue fabricationvascularization

Identifiers

PMID35356783
PMCPMC8959609
OpenAlexW4220985477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.